Sponsor Study ID:
Targeted Inta-arterial Gemcitabine vs. Continuation of IV Gemcitabine plus Nab-Paclitaxel following Injunction with sequential IV Gemcitabine plus Nab-Paclitaxel and Radiotherapy for Locally Advanced Pancreatic Cancer
To compare the Overall Survival, from time of randomization until death, between subjects receiving intra-arterial (IA) delivery of gemcitabine using the RenovoCath® device for 16 weeks vs. continuation of intravenous (IV) gemcitabine and nab-paclitaxel for 16 weeks in those with stable disease following induction therapy with IV gemcitabine and nab-paclitaxel and radiation treatment for unresectable locally advanced pancreatic adenocarcinoma.
If you would like to contact a MUSC study team member to learn more information about this study, click